A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma — G-HOPE-001  

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title: A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status Not yet recruiting

Clinical Trial Summary

This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Neoplasms

• NCT number: NCT06238843
• Study type: Interventional
• Source: Innovent Biologics (Suzhou) Co. Ltd.
• Contact: Shijie Liu
• Phone: +86 18701121959
• Email: shijie.liu@innoventbio.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: March 29, 2024
• Completion date: June 30, 2027